Medtronic Introduces MiniMed™ Mio™ Advance Infusion Set Enabling Fewer Insertion Steps for People with Diabetes in the U....
July 07 2020 - 9:00AM
Medtronic plc (NYSE:MDT), the global leader in medical
technology, today introduced the MiniMed™ Mio™ Advance infusion set
to all Medtronic insulin pump customers in the United States.
The MiniMed Mio Advance infusion set is the newest
addition to the MiniMed™ portfolio of infusion sets and gives
people using insulin pumps an optimal user experience with fewer
steps1.
The MiniMed Mio Advance infusion set is inserted
in only four steps — individuals simply peel, pinch, place, and
press to insert the infusion set.
The user-friendly design of the MiniMed Mio
Advance infusion set enables:
- One-handed insertion and flexibility to access more insertion
sites1 on the body such as the lower back or back of the
arm.
- A fully hidden needle before, during, and after insertion.
- Consistent insertion force with the built-in insertion device
(called a “serter”).
- Fewer insertion steps.
- Rotation of sites for better skin health and insulin
absorption1.
“Early feedback on the MiniMed Mio Advance
infusion set has been fantastic,” said Krista Sugerman, vice
president and general manager, Customer Retention and Experience
for the Diabetes Group at Medtronic. “Our goal is to continuously
improve and innovate core technologies to help people with diabetes
continue to experience greater freedom and better health. We are
excited to now make this infusion set available to more people and
make the daily management of diabetes easier for our
customers.”
Feedback from Medtronic Ambassadors using the
MiniMed Mio Advance infusion set has been overwhelmingly
positive:
“It was very easy to
remove off of her body and it was not painful.” – Carlos, father of
13-year-old Medtronic insulin pump user
”The Mio Advance is
easy to insert and pain free throughout the duration, I really like
not having to carry a separate inserter.” – Mark, Medtronic
insulin pump user
The MiniMed Mio Advance infusion set launched in
select countries outside the U.S. in 2018 with 85% of patients
preferring it to previous infusion sets2. MiniMed Mio Advance is
manufactured by ConvaTec’s Unomedical subsidiary and is only
available from Medtronic.
About the Diabetes Group at
Medtronic (www.medtronicdiabetes.com)Medtronic
is working together with the global community to change the way
people manage diabetes. The company aims to transform diabetes care
by expanding access, integrating care and improving outcomes, so
people living with diabetes can enjoy greater freedom and better
health.
About MedtronicMedtronic plc
(www.medtronic.com), headquartered in Dublin, Ireland, is among the
world’s largest medical technology, services and solutions
companies – alleviating pain, restoring health and extending life
for millions of people around the world. Medtronic employs more
than 90,000 people worldwide, serving physicians, hospitals and
patients in more than 150 countries. The company is focused on
collaborating with stakeholders around the world to take healthcare
Further, Together.
Any forward-looking statements are subject
to risks and uncertainties such as those described in Medtronic's
periodic reports on file with the Securities and Exchange
Commission. Actual results may differ materially from anticipated
results.
-end-
1 IFU and User Guide Comparison. Medtronic
data on file.2 Data on file from CIP 321: Pivotal Trial (Age
14-75). N=152. 2020;16 US sites.
Pam ReesePublic Relations+1-818-576-3398
Ryan WeispfenningInvestor Relations+1-763-505-4626
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2024 to May 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From May 2023 to May 2024